Exercise as an add-on treatment in individuals with schizophrenia: Results from a large multicenter randomized controlled trial
Carregando...
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2023
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER IRELAND LTD
Autores
MAURUS, Isabel
ROELL, Lukas
LEMBECK, Moritz
PAPAZOVA, Irina
GRESKA, David
MUENZ, Susanne
WAGNER, Elias
CAMPANA, Mattia
SCHWAIGER, Rebecca
SCHNEIDER-AXMANN, Thomas
Citação
PSYCHIATRY RESEARCH, v.328, article ID 115480, 11p, 2023
Resumo
Current treatment methods do not achieve recovery for most individuals with schizophrenia, and symptoms such as negative symptoms and cognitive deficits often persist. Aerobic endurance training has been suggested as a potential add-on treatment targeting both physical and mental health. We performed a large-scale multicenter, rater-blind, parallel-group randomized controlled clinical trial in individuals with stable schizophrenia. Participants underwent a professionally supervised six-month training comprising either aerobic endurance training (AET) or flexibility, strengthening, and balance training (FSBT, control group), follow-up was another six months. The primary endpoint was all-cause discontinuation (ACD); secondary endpoints included effects on psychopathology, cognition, functioning, and cardiovascular risk. In total, 180 participants were randomized. AET was not superior to FSBT in ACD and most secondary outcomes, with dropout rates of 59.55% and 57.14% in the six-month active phase, respectively. However, both groups showed significant improvements in positive, general, and total symptoms, levels of functioning and in cognitive performance. A higher training frequency additionally promoted further memory domains. Participants with higher baseline cognitive abilities were more likely to respond to the interventions. Our results support integrating exercise into schizophrenia treatment, while future studies should aim to develop personalized training recommendations to maximize exercise-induced benefits.
Palavras-chave
Cardiovascular risk, Clinical trial, Lifestyle intervention, Physical activity, Psychosis
Referências
- BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
- BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012
- Bredin SSD, 2022, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.753117
- Chekroud AM, 2021, WORLD PSYCHIATRY, V20, P154, DOI 10.1002/wps.20882
- Daumit GL, 2013, NEW ENGL J MED, V368, P1594, DOI 10.1056/NEJMoa1214530
- Dauwan M, 2021, J NEUROL, V268, P1222, DOI 10.1007/s00415-019-09493-9
- ENDICOTT J, 1976, ARCH GEN PSYCHIAT, V33, P766
- Falkai P, 2021, EUR ARCH PSY CLIN N, V271, P1201, DOI 10.1007/s00406-021-01282-8
- Firth J, 2019, LANCET PSYCHIAT, V6, P675, DOI 10.1016/S2215-0366(19)30132-4
- Fusar-Poli P, 2015, SCHIZOPHRENIA BULL, V41, P892, DOI 10.1093/schbul/sbu170
- Garber CE, 2011, MED SCI SPORT EXER, V43, P1334, DOI 10.1249/MSS.0b013e318213fefb
- Green MF, 2016, J CLIN PSYCHIAT, V77, P8, DOI 10.4088/JCP.14074su1c.02
- Herring MP, 2012, ARCH INTERN MED, V172, P101, DOI 10.1001/archinternmed.2011.696
- Jääskeläinen E, 2013, SCHIZOPHRENIA BULL, V39, P1296, DOI 10.1093/schbul/sbs130
- Laursen TM, 2019, SCHIZOPHR RES, V206, P284, DOI 10.1016/j.schres.2018.11.003
- Leucht S, 2007, NEUROPSYCHOPHARMACOL, V32, P1903, DOI 10.1038/sj.npp.1301325
- Leucht S, 2018, SCHIZOPHR RES, V201, P315, DOI 10.1016/j.schres.2018.05.009
- Liberman RP, 2002, INT REV PSYCHIATR, V14, P256, DOI 10.1080/0954026021000016905
- Liu-Ambrose T, 2010, ARCH INTERN MED, V170, P170, DOI 10.1001/archinternmed.2009.494
- Malchow B, 2015, SCHIZOPHRENIA BULL, V41, P847, DOI 10.1093/schbul/sbv020
- Maurus I, 2022, TRANSL PSYCHIAT, V12, DOI 10.1038/s41398-022-02155-x
- Maurus I, 2022, SCHIZOPHRENIA-UK, V8, DOI 10.1038/s41537-022-00269-1
- Maurus I, 2021, EUR ARCH PSY CLIN N, V271, P315, DOI 10.1007/s00406-020-01175-2
- Nielsen RE, 2015, ACTA PSYCHIAT SCAND, V131, P185, DOI 10.1111/acps.12374
- Pajonk FG, 2010, ARCH GEN PSYCHIAT, V67, P133, DOI 10.1001/archgenpsychiatry.2009.193
- Papiol S, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2017.131
- Rethorst CD, 2017, DEPRESS ANXIETY, V34, P1116, DOI 10.1002/da.22670
- Roe D, 2011, SCHIZOPHR RES, V131, P133, DOI 10.1016/j.schres.2011.05.023
- RStudio Team, 2020, RStudio. Integrated Development for R
- Sabe M, 2020, GEN HOSP PSYCHIAT, V62, P13, DOI 10.1016/j.genhosppsych.2019.11.002
- Scheewe TW, 2013, ACTA PSYCHIAT SCAND, V127, P464, DOI 10.1111/acps.12029
- Schuch FB, 2016, J AFFECT DISORDERS, V195, P40, DOI 10.1016/j.jad.2016.01.014
- Sedgwick O, 2021, PSYCHOL MED, V51, P707, DOI 10.1017/S0033291721000404
- Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi
- Shimada T, 2022, PSYCHIAT RES, V314, DOI 10.1016/j.psychres.2022.114656
- Suterwala AM, 2016, J CLIN PSYCHIAT, V77, P1036, DOI 10.4088/JCP.15m10104
- Szymczynska P, 2017, J PSYCHIATR RES, V90, P67, DOI 10.1016/j.jpsychires.2017.02.009
- van Praag H, 2005, J NEUROSCI, V25, P8680, DOI 10.1523/JNEUROSCI.1731-05.2005
- Vancampfort D, 2017, WORLD PSYCHIATRY, V16, P308, DOI 10.1002/wps.20458
- Vancampfort D, 2016, GEN HOSP PSYCHIAT, V39, P15, DOI 10.1016/j.genhosppsych.2015.11.008
- Villeneuve K, 2010, SCHIZOPHR RES, V121, P266, DOI 10.1016/j.schres.2010.04.003
- Vita A, 2018, CURR OPIN PSYCHIATR, V31, P246, DOI 10.1097/YCO.0000000000000407
- Wang PW, 2018, FRONT PSYCHIATRY, V9, DOI 10.3389/fpsyt.2018.00167
- Yu Q, 2022, SPORTS MED-OPEN, V8, DOI 10.1186/s40798-022-00529-5